Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGN NYSE:IKT NASDAQ:IMAB NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$8.27+5.2%$6.47$2.65▼$9.85$423.10M-0.27374,538 shs104,434 shsIKTInhibikase Therapeutics$1.54+0.7%$1.65$1.42▼$4.20$114.76M0.89175,922 shs75,105 shsIMABI-Mab$4.22-3.9%$4.47$0.60▼$6.79$344.61M1.452.17 million shs1.36 million shsOCGNOcugen$1.61+5.2%$1.36$0.52▼$1.90$470.61M4.26.37 million shs3.63 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene+5.22%-11.55%+18.48%+123.51%-11.46%IKTInhibikase Therapeutics+0.65%-1.91%-10.47%-12.99%-36.63%IMABI-Mab-3.87%-26.86%+18.54%+100.00%+217.29%OCGNOcugen+5.23%+0.63%-1.83%+47.71%+76.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$8.27+5.2%$6.47$2.65▼$9.85$423.10M-0.27374,538 shs104,434 shsIKTInhibikase Therapeutics$1.54+0.7%$1.65$1.42▼$4.20$114.76M0.89175,922 shs75,105 shsIMABI-Mab$4.22-3.9%$4.47$0.60▼$6.79$344.61M1.452.17 million shs1.36 million shsOCGNOcugen$1.61+5.2%$1.36$0.52▼$1.90$470.61M4.26.37 million shs3.63 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene+5.22%-11.55%+18.48%+123.51%-11.46%IKTInhibikase Therapeutics+0.65%-1.91%-10.47%-12.99%-36.63%IMABI-Mab-3.87%-26.86%+18.54%+100.00%+217.29%OCGNOcugen+5.23%+0.63%-1.83%+47.71%+76.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 2.75Moderate Buy$19.50135.79% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$8.00419.48% UpsideIMABI-Mab 2.86Moderate Buy$7.6781.67% UpsideOCGNOcugen 2.33Hold$7.00334.78% UpsideCurrent Analyst Ratings BreakdownLatest IKT, ENGN, IMAB, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.0010/17/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $9.0010/14/2025ENGNenGeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMABI-MabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/3/2025IMABI-MabLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.0010/3/2025IMABI-MabLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/27/2025ENGNenGeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IMABI-MabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AIMABI-MabN/AN/AN/AN/A$2.47 per shareN/AOCGNOcugen$4.75M98.99N/AN/A$0.10 per share16.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$55.14M-$1.90N/AN/AN/AN/A-39.86%-34.15%12/18/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$0.91N/AN/AN/AN/A-350.63%-201.82%N/AIMABI-Mab-$22.23M-$0.36N/AN/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)OCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/5/2025 (Estimated)Latest IKT, ENGN, IMAB, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025IMABI-Mab-$0.07N/AN/AN/AN/AN/A11/5/2025Q3 2025OCGNOcugen-$0.06N/AN/AN/A$0.44 millionN/A9/11/2025Q3 2025ENGNenGene-$0.5084-$0.57-$0.0616-$0.57N/AN/A8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGene$1.5819.12%N/AN/A N/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0910.3410.34IKTInhibikase TherapeuticsN/A0.850.85IMABI-MabN/A22.8222.82OCGNOcugen9.181.831.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%IKTInhibikase Therapeutics3.81%IMABI-Mab38.38%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipENGNenGene10.40%IKTInhibikase Therapeutics7.30%IMABI-Mab22.10%OCGNOcugen4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3151.19 million45.87 millionN/AIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableIMABI-Mab38081.66 million63.61 millionOptionableOCGNOcugen80292.31 million279.39 millionOptionableIKT, ENGN, IMAB, and OCGN HeadlinesRecent News About These CompaniesOcugen, Inc. Scheduled to Host Conference Call for Third Quarter 2025 Financial Results on November 5, 2025October 23 at 7:50 AM | quiverquant.comQOcugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial ResultsOctober 23 at 7:30 AM | globenewswire.comOcugen (NASDAQ:OCGN) Trading Up 1.3% - Still a Buy?October 21, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Shares Down 7.4% - Should You Sell?October 11, 2025 | marketbeat.comWeiss Ratings Reaffirms Sell (E+) Rating for Ocugen (NASDAQ:OCGN)October 10, 2025 | marketbeat.comOcugen to Highlight Gene Therapy Pipeline at Key Industry and Investor ConferencesOctober 6, 2025 | msn.comOcugen (NASDAQ:OCGN) Hits New 52-Week High - Here's WhyOctober 3, 2025 | marketbeat.comOcugen to Present at Industry and Investor Conferences in October 2025October 2, 2025 | markets.businessinsider.comOcugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness DiseasesOctober 2, 2025 | quiverquant.comQTraders Buy High Volume of Ocugen Call Options (NASDAQ:OCGN)October 1, 2025 | marketbeat.comGoldman Sachs Group Inc. Lowers Holdings in Ocugen, Inc. $OCGNSeptember 27, 2025 | marketbeat.comOcugen: A Retinal Disease Juggernaut In The MakingSeptember 23, 2025 | seekingalpha.comOcugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in KoreaSeptember 20, 2025 | msn.comForecasting The Future: 4 Analyst Projections For OcugenSeptember 19, 2025 | benzinga.comOcugen (OCGN): Evaluating Valuation Following Exclusive Korean Licensing Deal for Gene Therapy OCU400September 18, 2025 | finance.yahoo.comWhy Ocugen (OCGN) Is Up 16.5% After Licensing OCU400 Gene Therapy Rights to KwangdongSeptember 16, 2025 | finance.yahoo.comOcugen Signs Exclusive License Agreement with KwangdongSeptember 16, 2025 | tipranks.comOcugen executes licensing agreement with Kwangdong PharmaceuticalSeptember 15, 2025 | msn.comOcugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 MillionSeptember 15, 2025 | quiverquant.comQOcugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaSeptember 15, 2025 | globenewswire.comOcugen CEO to Speak at Investor Conferences in New York and MunichSeptember 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?By Leo Miller | October 3, 2025IKT, ENGN, IMAB, and OCGN Company DescriptionsenGene NASDAQ:ENGN$8.27 +0.41 (+5.22%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.41 +0.14 (+1.68%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Inhibikase Therapeutics NYSE:IKT$1.54 +0.01 (+0.65%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 10/24/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.I-Mab NASDAQ:IMAB$4.22 -0.17 (-3.87%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.39 +0.18 (+4.15%) As of 10/24/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Ocugen NASDAQ:OCGN$1.61 +0.08 (+5.23%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.62 +0.01 (+0.62%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
